Ironwood Pharmaceuticals will pay $100 million upfront to AstraZeneca for exclusive U.S. rights to lesinurad, the active ingredient of Zurampic.
AstraZeneca will manufacture and supply Zurampic, and Ironwood will pay tiered single-digit royalties on product sales and other milestones of up to $165 million.
The deal includes a fixed-dose combination oflesinurad and allopurinol. The companies expect to file an application for the combination later this year.
Tom McCourt, Ironwood’s chief commercial officer, says the deal aims to expand the company’s gout franchise, with possibly five product launches by 2020.